YD Bio Ltd
Research YD Bio Ltd (YDES) on Bullrun: market cap USD 331.49M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerYDES
- ExchangeNASDAQ
- CountryTaiwan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 331.49M
- Financial periodFY2025
- RevenueUSD 596.82K
- Revenue growth16.9%
- Net income-USD 8.31M
- Free cash flow-USD 8.04M
- Gross margin28.1%
Valuation Snapshot
latest market cap is USD 331.49M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 596.82K | -USD 8.31M | -USD 8.04M | 28.1% | -0.12 | USD 6.01M | USD 6.76K | -USD 2.86M |
| FY2024 | USD 510.36K | -USD 1.41M | -USD 4.75M | 30.4% | -0.02 | USD 3.13M | USD 22.56K | USD 6.59M |
| FY2023 | USD 350.13K | USD 13.56K | -USD 55.95K | 43.8% | 0 | USD 87.10K | USD 47.58K | USD 22.99K |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 331.49M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 859.66M | n/a | n/a | n/a |
About YD Bio Ltd
YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs. The company is based in Taipei, Taiwan.
Related stock research
Other Healthcare stocks
Jyong Biotech Ltd (MENS)
HLB Co., Ltd. (028300)
Celltrion, Inc. (068270)
Tubacex (0KD1)
Neovacs S.A. (0LW0)
TME PHARM.CONF.IPO EO 1- (0N6A)
Selvaag Bolig ASA (0Q92)
Camurus AB (0RD1)
ALTEOGEN Inc. (196170)
Adalta Ltd (1AD)
ONCOARENDI THERAP ZY-01 (1B1)
WUXI BIOLOGICS-00000083 (1FW2)
Frequently asked questions
What is YD Bio Ltd's market cap?
YD Bio Ltd's market capitalization is USD 331.49M.
What does YD Bio Ltd do?
YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs. The company is based in Taipei, Taiwan.